Background and Purpose of Fundraising
It is said that there are more than 30,000 diseases for which there are no effective treatments, making the development of new drugs extremely important. However, the difficulty of drug discovery in the pharmaceutical industry is increasing year by year, and development efficiency is declining. Since it takes about 10 years and a huge cost of about 100 billion yen (*1) for a pharmaceutical company to bring a drug to the market, new technologies and development methods are needed.
The biopharmaceutical molecule design technology provided by MOLCURE can automatically perform large-scale screening and molecule design using AI and robotics, and compared to existing methods, can streamline the discovery cycle of drug candidate molecules to less than one-tenth, discover more than 10 times more new drug It is also possible to discover 10 times more new drug candidates and design molecules with superior properties that are difficult to discover using conventional methods. Currently, the company is using this technology to develop new drugs in partnership with pharmaceutical companies.
In particular, in the joint drug discovery pipeline development conducted with a pharmaceutical company in 2021, the company succeeded in designing a large number of molecules with 100 times more binding power than existing biotechnological experiment-driven methods, and also succeeded in designing molecules that are effective against a certain drug target for the first time in the world, This is the world's first success in designing molecules that are effective against a certain drug target, and is a major achievement in the case of AI-based drug discovery.
The company will use the funding to accelerate joint development with major pharmaceutical companies and global expansion, and promote business development to improve the quality of life (QOL) of patients.
1 [citation needed] Nat Rev Drug Discov. 2010 Mar;9(3):203-14.
"How to improve R&D productivity: the pharmaceutical industry's grand challenge."

Become the de facto standard for AI utilization by domestic and foreign pharmaceutical companies in partnership
The technology provided by MOLCURE is supported by its ability to search for an overwhelmingly large number of superior drug molecules and the high-quality expertise in AI x biopharmaceutical development provided by a group of top researchers in the industry. To date, MOLCURE has been used in 10 projects by a cumulative total of 7 major pharmaceutical companies and major pharmaceutical biotech companies, including Twist Bioscience (U.S.) and Nippon Chemiphar (*2).
2 Examples of partners engaged in joint drug discovery pipeline development as of August 18, 2021

The following press release, dated July 27, 2021, from Dr. Emily Leproust, CEO and co-founder of Twist Bioscience, regarding joint drug discovery pipeline development (https://molcure.com/2021/07/27/twist-bioscience-jp/(Comments have been received from the following.
Twist Bioscience continues to innovate and incorporate cutting-edge antibody discovery and optimization methodologies into our processes, and MOLCURE's AI technology provides leverage for our proprietary antibody discovery and optimization efforts and technologies, enabling us to enhance our internal antibody pipeline. and enhance our in-house antibody drug pipeline. Their AI technology, together with our antibody drug library and NGS sequencing data, will enable us to explore additional lead antibodies. We look forward to incorporating the lead antibodies from this collaboration into our internal pipeline."
About Twist Bioscience, Inc.
Twist Bioscience, a fast-growing leader in synthetic biology and genomics, has developed a DNA synthesis platform that is a disruptive innovation for the industrialization of biotechnology. At the core of this platform is a proprietary state-of-the-art technology that "writes" DNA onto silicon chips to produce synthetic DNA, which Twist leverages to produce a wide range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS), and antibody libraries for drug discovery and development. based products, including synthetic genes, tools for next-generation sequencing (NGS), and antibody libraries for drug discovery and development. The company is also exploring the long-term potential of digital data storage in DNA and biologics drug discovery.Twist will manufacture products for use in a variety of industries, including healthcare, industrial chemistry, agriculture, and academic research.
About Nippon Chemiphar
Founded in 1950, Nippon Chemiphar is a company engaged in the business of prescription pharmaceuticals, clinical diagnostics, and healthcare. The company has three growth strategies: "generic drugs," "alkalizing agents," and "self-developed drug discovery," and aims to expand the results of these strategies domestically and internationally. In the area of in-house drug discovery, the company is engaged in the development of breakthrough new drugs and drug repositioning of existing drugs through "venture-type drug discovery research" focused on exploratory research, and has recently succeeded in identifying several promising candidate compounds for new drug development.
The company will continue to utilize cutting-edge technologies such as AI to discover further new drug candidates, improve the quality of drug molecules, and realize more efficient drug discovery research.
Underwriter's Comment
Mr. Atsushi Fujii, Partner, Jafco Group K.K.
MOLCURE is a team of talented members who share a strong desire to "realize a world where there is a special medicine for every disease" and who share the same passion in the fields of biotechnology, AI, and robotics. Our drug design platform has already reached the point where it can create drug candidates with performance superior to that of manually developed drugs, and we have decided to invest in MOLCURE in order to take on the challenge of updating drug development together with MOLCURE. We are confident that MOLCURE will grow globally as an AI drug discovery startup from Japan.
Ms. Natsumi Negishi, Partner, STRIVE Corporation
As in other industries, innovative AI-based methods are rapidly spreading in drug discovery, especially in the U.S. MOLCURE has been developing AI-based technologies since its founding in 2013 and is a leading AI drug discovery company in Japan. We have assembled talented members in the fields of evolutionary molecular engineering, AI, and robotics, and have already produced promising drug candidate molecules in collaboration with our clients. We have decided to invest in this company because we strongly feel the market expansion and our company's potential in the future. We hope that more new drugs will be created through our platform in the future.
Mr. Makoto Hasegawa, Manager, Investment Department, SBI Investment Co.
MOLCURE possesses high-level proprietary technologies in the fields of biotechnology, robotics, and AI. We have decided to invest in MOLCURE because we believe that the combination of these technologies has the potential to bring a breakthrough in drug development, which is becoming increasingly difficult year by year, by improving the efficiency of drug candidate molecule search. We are very pleased to be working with MOLCURE through this investment, and we hope that this technology will lead to the creation of innovative drugs that satisfy unmet medical needs as soon as possible.
Mr. Hiroki Yoshioka, Senior Associate, Investment Division, Japan Post Capital Co.
As there are still many diseases for which there is no cure, we believe that MOLCURE's biopharmaceutical development platform will contribute to the faster discovery of new treatments and new drug candidates that have not been found using conventional methods. We hope that MOLCURE, together with its many pharmaceutical partners, will achieve business growth and make more diseases treatable in the future.
Mr. Masahide Yasumoto, Director, Executive Officer, General Manager of Corporate Planning Department, Nippon Chemiphar Co.
We have been taking an equity stake in MOLCURE since November 2018 with the aim of developing breakthrough drugs for patients suffering from diseases for which there are still no adequate treatments. We have launched an initiative to innovate drug discovery research methods by integrating the company's AI drug discovery system with our drug discovery research infrastructure, and are currently conducting joint research in specific drug discovery target areas. We expect that MOLCURE's business growth and efforts to form a business alliance with us will be further accelerated by this further large-scale fundraising.
About MOLCURE Corporation
| name of company | MOLCURE Corporation |
| Establishment | May 2013 |
| capital stock | AIRBIC A07, 7-7 Shinkawasaki, Saiwai-ku, Kawasaki-shi, Kanagawa, Japan |
| representative | Representative Director: Takashi Ogawa |
| Business Overview | Development and provision of a drug discovery platform that integrates artificial intelligence, evolutionary molecular engineering, and experimental automation for peptide and antibody molecular design. |
| uniform resouce locator | https://molcure.com |









